Propella Signs a License Agreement with Jiangsu Aosaikang to Develop and Commercial CGS-200-5 for the Treatment of Pain in Greater China
Shots:
- Propella to receive an up front & is also eligible to receive regulatory and sales milestones along with royalties on future product sales. ASK Pharm to get exclusive rights to develop, manufacture, and commercialize CGS-200-05 in Greater China
- In the P-II study, CGS-200-5 showed a reduction in pain by 50% in patients with mod. to sev. osteoarthritis of the knee while demonstrating good safety and tolerability. The therapy also demonstrated highly durable pain relief while the clinical studies shown a reduction in OA knee pain
- The agreement helps to advance the oncology pipeline including Propella’s PRL-02 for the treatment of advanced prostate cancer
Ref: Globe Newswire | Image: Propella
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
